---
companies:
- category: unknown
  confidence: medium
  context: Welcome everyone to the AI and Business Podcast. I'm Matthew Damello, Editorial
    Director here at
  name: Business Podcast
  position: 31
- category: unknown
  confidence: medium
  context: come everyone to the AI and Business Podcast. I'm Matthew Damello, Editorial
    Director here at Emerge AI Research. T
  name: Matthew Damello
  position: 53
- category: unknown
  confidence: medium
  context: the AI and Business Podcast. I'm Matthew Damello, Editorial Director here
    at Emerge AI Research. Today's guest is Anth
  name: Editorial Director
  position: 70
- category: unknown
  confidence: medium
  context: . I'm Matthew Damello, Editorial Director here at Emerge AI Research. Today's
    guest is Anthony Mikolachik, Vice Presid
  name: Emerge AI Research
  position: 97
- category: unknown
  confidence: medium
  context: ctor here at Emerge AI Research. Today's guest is Anthony Mikolachik, Vice
    President of Commercial Strategy at IQVIA T
  name: Anthony Mikolachik
  position: 134
- category: unknown
  confidence: medium
  context: AI Research. Today's guest is Anthony Mikolachik, Vice President of Commercial
    Strategy at IQVIA Technologies. Wit
  name: Vice President
  position: 154
- category: unknown
  confidence: medium
  context: '''s guest is Anthony Mikolachik, Vice President of Commercial Strategy
    at IQVIA Technologies. With more than 30 years of'
  name: Commercial Strategy
  position: 172
- category: unknown
  confidence: medium
  context: olachik, Vice President of Commercial Strategy at IQVIA Technologies. With
    more than 30 years of experience in clinica
  name: IQVIA Technologies
  position: 195
- category: unknown
  confidence: medium
  context: ecutive thought leaders, everyone from the CIO of Goldman Sachs to the
    head of AI at Raytheon and AI pioneers lik
  name: Goldman Sachs
  position: 1136
- category: unknown
  confidence: medium
  context: o the head of AI at Raytheon and AI pioneers like Yoshua Bengio. With nearly
    a million annual listeners, AI and B
  name: Yoshua Bengio
  position: 1201
- category: unknown
  confidence: medium
  context: eve you can help other leaders move the needle on AI ROI, visit emerj.com
    and fill out our Thought Leader
  name: AI ROI
  position: 1667
- category: unknown
  confidence: medium
  context: eedle on AI ROI, visit emerj.com and fill out our Thought Leader submission
    form. That's emerj.com and click on Be
  name: Thought Leader
  position: 1708
- category: unknown
  confidence: medium
  context: urning AI into ROI, join us at Emerge's Vision to Value AI Infrasummit.
    We're enterprise leaders from Google, Microsoft,
  name: Value AI Infrasummit
  position: 2026
- category: tech
  confidence: high
  context: lue AI Infrasummit. We're enterprise leaders from Google, Microsoft, IBM,
    and more share how they build, s
  name: Google
  position: 2078
- category: tech
  confidence: high
  context: nfrasummit. We're enterprise leaders from Google, Microsoft, IBM, and more
    share how they build, secure, and
  name: Microsoft
  position: 2086
- category: tech
  confidence: high
  context: ', IBM, and more share how they build, secure, and scale AI infrastructure
    for real business impact. Registra'
  name: Scale Ai
  position: 2145
- category: unknown
  confidence: medium
  context: This podcast is supported by Google. Hey folks, Stephen Johnson here, co-founder
    of NotebookLM. As an author, I'v
  name: Stephen Johnson
  position: 2451
- category: unknown
  confidence: medium
  context: rt of it, if you think back to the early 2000s of Palm Pilots, some of
    the first electronic implementations of
  name: Palm Pilots
  position: 4271
- category: unknown
  confidence: medium
  context: implementations of those things were done on the Palm Pilot. So let me
    put this in another context for you. T
  name: Palm Pilot
  position: 4362
- category: unknown
  confidence: medium
  context: ity. Let me give you just a real quick statistic. The IQVIA Institute does
    a lot of research in obesity. There are two
  name: The IQVIA Institute
  position: 7244
- category: unknown
  confidence: medium
  context: ople's how they're feeling and how they're doing. The SF-36 is another
    one that's incredibly popular for m
  name: The SF
  position: 8281
- category: unknown
  confidence: medium
  context: have a scale at home to be able to collect that. And I was visiting a sponsor
    about a year and a half ag
  name: And I
  position: 11589
- category: unknown
  confidence: medium
  context: issue behind scales is how do you make sure that Uncle Fester isn't jumping
    on that scale and weighing himself,
  name: Uncle Fester
  position: 11900
- category: unknown
  confidence: medium
  context: ll of a sudden you get attributed to that weight? Or Joey decides that
    this is a fun thing to play with. So
  name: Or Joey
  position: 12018
- category: unknown
  confidence: medium
  context: e are tools in place. IQVIA has a tool called the ECOA Accelerator, and
    what that tool does is when you put in your
  name: ECOA Accelerator
  position: 15623
- category: unknown
  confidence: medium
  context: 'e results that you''re looking for. And that''s our COA Accelerator is
    one of those tools that are doing that.


    It ma'
  name: COA Accelerator
  position: 16501
- category: unknown
  confidence: medium
  context: ot of them want to do food diaries, and I get it. So I always ask the question,
    what's your intent with
  name: So I
  position: 20607
- category: media/research
  confidence: high
  context: The organization hosting the AI and Business Podcast and where the speaker
    is the Editorial Director.
  name: Emerge AI Research
  source: llm_enhanced
- category: tech/life sciences
  confidence: high
  context: The company where the guest, Anthony Mikolachik, is the Vice President
    of Commercial Strategy.
  name: IQVIA Technologies
  source: llm_enhanced
- category: finance
  confidence: high
  context: Mentioned as an example of an organization whose CIO has been featured
    on the podcast.
  name: Goldman Sachs
  source: llm_enhanced
- category: tech/defense
  confidence: high
  context: Mentioned as an example of an organization whose head of AI has been featured
    on the podcast.
  name: Raytheon
  source: llm_enhanced
- category: media/tech
  confidence: high
  context: The website for Emerge AI Research, used for thought leader submissions
    and event registration.
  name: emerj.com
  source: llm_enhanced
- category: tech
  confidence: high
  context: Mentioned as an enterprise leader sharing insights at Emerge's Vision to
    Value AI Infrasummit, and as the supporter of the podcast.
  name: Google
  source: llm_enhanced
- category: tech
  confidence: high
  context: Mentioned as an enterprise leader sharing insights at Emerge's Vision to
    Value AI Infrasummit.
  name: Microsoft
  source: llm_enhanced
- category: tech
  confidence: high
  context: Mentioned as an enterprise leader sharing insights at Emerge's Vision to
    Value AI Infrasummit.
  name: IBM
  source: llm_enhanced
- category: tech
  confidence: high
  context: An AI-first tool for organizing ideas, co-founded by Stephen Johnson.
  name: NotebookLM
  source: llm_enhanced
- category: tech/hardware
  confidence: high
  context: Referenced historically as one of the first devices used for electronic
    implementations of clinical outcome assessments (ECOAs) in the early 2000s.
  name: Palm Pilot
  source: llm_enhanced
- category: tech/software
  confidence: medium
  context: Used as an analogy to describe a sophisticated questionnaire/COA, described
    as 'SurveyMonkey on steroids'.
  name: SurveyMonkey
  source: llm_enhanced
- category: government/regulatory
  confidence: high
  context: The Food and Drug Administration, mentioned for mandating the use of patient-reported
    outcomes (COAs) around 2011/2012.
  name: FDA
  source: llm_enhanced
- category: research/life sciences
  confidence: high
  context: The research arm of IQVIA, mentioned for conducting research in obesity
    drug development.
  name: IQVIA Institute
  source: llm_enhanced
- category: pharma/tech
  confidence: high
  context: A currently marketed obesity compound mentioned in the context of competitive
    development.
  name: Wegovy
  source: llm_enhanced
- category: pharma/tech
  confidence: high
  context: A currently marketed obesity compound mentioned in the context of competitive
    development.
  name: Zepbound
  source: llm_enhanced
- category: tech/life sciences
  confidence: high
  context: The company that developed the 'ECOA Accelerator' tool.
  name: IQVIA
  source: llm_enhanced
- category: pharmaceutical/biotech
  confidence: medium
  context: Mentioned in the context of obesity trials and patient dropout rates related
    to the effectiveness of GLP-1 drugs.
  name: GLP-1
  source: llm_enhanced
date: 2025-09-16 06:00:00 +0000
duration: 32
has_transcript: false
layout: episode
llm_enhanced: true
original_url: https://traffic.libsyn.com/secure/techemergence/Business_-_9.16.25_-_Anthony_Mikulaschek.mp3?dest-id=151434
processing_date: 2025-10-04 18:31:24 +0000
quotes:
- length: 152
  relevance_score: 4
  text: But first, are you driving AI transformation at your organization, or maybe
    you're guiding critical decisions on AI investments, strategy, or deployment
  topics:
  - investment
- length: 54
  relevance_score: 4
  text: You have to pay people for their intellectual property
  topics: []
- length: 145
  relevance_score: 3
  text: We're enterprise leaders from Google, Microsoft, IBM, and more share how they
    build, secure, and scale AI infrastructure for real business impact
  topics: []
- length: 57
  relevance_score: 3
  text: So answering questions, and you have to take a look at it
  topics: []
- length: 216
  relevance_score: 3
  text: And so you have to be cognizant of that and, you know, keep them engaged,
    keep them positive about the study and about the results of the study and the
    results that they could see, and not making it overly burdensome
  topics: []
- length: 126
  relevance_score: 3
  text: And what we found out about four years ago is that that's great, but more
    than that is they want to be told what the data says
  topics: []
- length: 124
  relevance_score: 3
  text: That enabling that productivity for the site is, I think, one of the biggest
    things that we've done to help ease site burden
  topics: []
- impact_reason: Provides a striking statistic (173 compounds) that quantifies the
    intense competition in the obesity therapeutic area.
  relevance_score: 10
  source: llm_enhanced
  text: There are two or three compounds currently marketed for obesity... There are
    173 compounds in development. It is an extremely competitive field, extremely
    dense field of all the different types of therapies that are coming out.
  topic: Business/Market Insight
- impact_reason: 'Crucial strategic insight: translation is insufficient; cultural
    adaptation (nuance) is required for valid data collection.'
  relevance_score: 10
  source: llm_enhanced
  text: The instrument needs to be adapted not only to be translated, but then adapted
    for the actual cultural nuance for that particular region.
  topic: Strategy/Localization
- impact_reason: A powerful, concrete example illustrating the danger of technology
    assumptions leading to failed data capture in global trials.
  relevance_score: 10
  source: llm_enhanced
  text: A lot of countries in Asia, they don't use an iPhone. They use chopsticks.
    So what if an assessment said, could you use your iPhone today? We wouldn't think
    anything about that. It's just a normal operating thing for us, but that actually
    has zero meaning in another country.
  topic: Cautionary Tale/Localization
- impact_reason: 'Highlights a critical, non-technical operational hurdle in remote
    data collection: data attribution and security/integrity at the patient level.'
  relevance_score: 10
  source: llm_enhanced
  text: The number one issue behind scales is how do you make sure that Uncle Fester
    isn't jumping on that scale and weighing himself, and all of a sudden you get
    attributed to that weight?
  topic: Operational Challenge/Data Integrity
- impact_reason: 'Directly links AI capabilities to solving one of the most complex
    challenges discussed: global localization and cultural nuance.'
  relevance_score: 10
  source: llm_enhanced
  text: We have these new capabilities like AI that can really minimize the localization
    problem you brought up before.
  topic: AI Application
- impact_reason: 'Defines the modern strategic goal: digitizing processes specifically
    to maximize compatibility and utility with emerging AI tools.'
  relevance_score: 10
  source: llm_enhanced
  text: How do we make this process digitized and then how do we make it best suitable
    to apply to those AI capabilities, capabilities that we know will solve for localization
    challenges?
  topic: Digital Strategy/AI Integration
- impact_reason: Identifies technology sprawl (using too many disparate systems) as
    the primary driver of site burden, advocating for platform consolidation.
  relevance_score: 10
  source: llm_enhanced
  text: The number one way to do that [limit site burden] is to limit the number of
    pieces of technology that they use because the site, they might be participating
    in three or four different trials... They're dealing with 60 different pieces
    of technology.
  topic: Site Burden/Tech Consolidation
- impact_reason: Details the complexity of digital COA management, emphasizing non-technical
    hurdles like IP rights, copyright agreements, and localization (translations).
  relevance_score: 10
  source: llm_enhanced
  text: I'm talking about doing a digital implementation of those COAs. How do you
    manage that library from the standpoint of do you have translations in there or
    don't you have translations in there? Do you have collaboration agreements in
    place with copyright holders because all that stuff's not all public domain.
  topic: Intellectual Property/Digital Strategy
- impact_reason: 'Points to a specific, high-value application of AI in clinical trials:
    automating the generation of complex regulatory documentation.'
  relevance_score: 10
  source: llm_enhanced
  text: There's some other areas with systems these days, with AI technology these
    days, you can auto-generate clinical regulatory documentation within your system.
  topic: Artificial Intelligence/Automation
- impact_reason: Clearly articulates the critical business pressure driving speed—patent
    expiration and the race to market.
  relevance_score: 10
  source: llm_enhanced
  text: It's getting things done faster because these companies that own these compounds,
    that own these therapies, they're on the clock in terms of how long they own the
    patent and before it goes generic.
  topic: Business/Market Pressure
- impact_reason: Pinpoints the key regulatory driver (FDA mandate) that accelerated
    the adoption of patient-reported outcomes.
  relevance_score: 9
  source: llm_enhanced
  text: They really came into prominence about 2012, 2011, when the FDA really mandated
    that they wanted to see more data as it relates to how the patient is actually
    feeling and doing as a part of their therapy.
  topic: Regulation & Strategy
- impact_reason: Identifies obesity/metabolic studies as the current high-growth area,
    driven by specific drug classes (GLP-1s).
  relevance_score: 9
  source: llm_enhanced
  text: Metabolic studies, which obesity fits into, is a rapidly growing area with
    the increase of GLP-1s and other therapies that are coming out to support obesity.
  topic: Industry Trend
- impact_reason: A stark warning about the speed of market erosion in competitive
    areas like obesity, forcing developers to seek differentiators early.
  relevance_score: 9
  source: llm_enhanced
  text: If your compound is showing promise [in obesity trials], well, chances are
    Wegovy and Zepbound are going to be generic by the time you get through your Phase
    1, 2, and 3 trials.
  topic: Business Strategy/Risk
- impact_reason: Identifies the shift from purely questionnaire-based data (oncology)
    to integrating data from connected devices in obesity trials.
  relevance_score: 9
  source: llm_enhanced
  text: Obesity trials has the additional challenge of just collecting the data because...
    For weight loss and obesity, you might have a blood glucose monitor on you. So
    that's a device, connected devices.
  topic: Technology Integration
- impact_reason: Positions ECOAs as the crucial 'bridge' technology necessary to connect
    disparate parts of the clinical trial ecosystem.
  relevance_score: 9
  source: llm_enhanced
  text: COAs as they make this transition into digitization are sort of the barrier
    where, oh, if we're going to fix any part of how both sides of this river, you
    know, get across to each other, it's how we build this bridge of the electronic
    clinical outcome assessments.
  topic: Technology Role
- impact_reason: Emphasizes the high stakes of COA data quality when it constitutes
    the primary endpoint, directly impacting regulatory success.
  relevance_score: 9
  source: llm_enhanced
  text: When your primary endpoint data is data from a COA, then all of a sudden,
    that just that opens up an entire door of issues and concerns that you need to
    implement and take action against in your clinical trial.
  topic: Regulatory/Data Quality
- impact_reason: A stark, definitive statement on the non-negotiable nature of primary
    endpoint data collection in clinical trials.
  relevance_score: 9
  source: llm_enhanced
  text: If you don't have that data, you're not doing any regulatory filing.
  topic: Regulatory Compliance
- impact_reason: 'A crucial strategic insight: successful global data collection requires
    cultural translation, not just linguistic translation.'
  relevance_score: 9
  source: llm_enhanced
  text: Not only will this data need to be translated between languages, they really
    need to be translated between cultures.
  topic: Globalization/Culture
- impact_reason: Connects technology-aided analysis (identifying duplication) directly
    to the core metric of patient centricity and burden reduction.
  relevance_score: 9
  source: llm_enhanced
  text: If you use these five instruments, you have these duplicative elements. So
    now we start talking about patient centricity and patient burden, which one of
    these instruments or combination instruments is going to be the least burdensome
    for the patient?
  topic: Patient Centricity/Efficiency
- impact_reason: Powerful anecdotal evidence showing that poor wording in digital
    instruments can actively harm engagement due to stigma.
  relevance_score: 9
  source: llm_enhanced
  text: They had a visceral reaction to the questionnaires because just based on how
    the questionnaires were worded because of the stigma associated with obesity.
  topic: Qualitative Feedback/Design Flaws
- impact_reason: 'A key shift in user expectation: moving from raw data access to
    actionable, pre-analyzed insights (e.g., compliance reports).'
  relevance_score: 9
  source: llm_enhanced
  text: What we found out about four years ago is that that's great, but more than
    that is they want to be told what the data says.
  topic: Data Analytics/Actionability
- impact_reason: Describes a successful proactive monitoring system that offloads
    cognitive work from site staff, enabling them to focus on patient care.
  relevance_score: 9
  source: llm_enhanced
  text: We implemented a whole compliance monitoring functionality that basically
    said, we will check every single day... what the compliance to all your patients
    are, and then we will let you know if they're out of compliance so the site can
    follow up with them.
  topic: Proactive Monitoring/Automation
- impact_reason: Identifies the regulatory shift toward BYOD acceptance (driven by
    COVID) as a major enabler for cost-effectiveness and patient convenience in eCOA.
  relevance_score: 9
  source: llm_enhanced
  text: One thing that really helped our industry from a COVID standpoint was that
    the regulatory bodies really started accepting BYOD, using BYOD strategies, bring-your-own-device
    strategies for eCOA collection.
  topic: Regulatory Change/BYOD
- impact_reason: 'A foundational strategic insight: despite technological evolution
    over 30 years, the core business driver for tech adoption in clinical trials remains
    speed.'
  relevance_score: 9
  source: llm_enhanced
  text: The primary objective has not changed at all from applying technology to the
    clinical process, and that is speed.
  topic: Strategy/Industry Goal
- impact_reason: 'Offers a nuanced warning: technology alone doesn''t guarantee speed;
    the goal is operational invisibility and reliability (''stay off the critical
    path'').'
  relevance_score: 9
  source: llm_enhanced
  text: Now, I cannot say if you just deploy the latest and greatest ECOA platform
    that you're going to be going faster, but the one thing that I can say is that
    we're going to stay off the critical path, and we don't want to be the topic of
    any meeting, to be honest with you.
  topic: Implementation Caution/Operational Excellence
- impact_reason: Provides the foundational definition for the core technology being
    discussed (ECOA), essential for audience understanding.
  relevance_score: 8
  source: llm_enhanced
  text: ECOA is the electronic implementation of a clinical outcome assessment.
  topic: Technology Definition
- impact_reason: Offers a highly relatable, non-technical analogy for executives to
    quickly grasp the function of an ECOA.
  relevance_score: 8
  source: llm_enhanced
  text: Think of like a SurveyMonkey on steroids. It's a questionnaire.
  topic: Technology Analogy
- impact_reason: Highlights oncology's sustained dominance in R&D spending, signaling
    where major industry resources are concentrated.
  relevance_score: 8
  source: llm_enhanced
  text: Oncology has always led the industry for a good number of years in terms of
    the amount of spend.
  topic: Business/Industry Trend
- impact_reason: Emphasizes the massive scale and complexity of global trial localization
    required for data integrity.
  relevance_score: 8
  source: llm_enhanced
  text: These are global trials. So sometimes we just take it for granted. We just
    read everything in English, but we could have a global trial in 60 different countries
    with about 150 different languages.
  topic: Operational Challenge
- impact_reason: Shows how competitive pressure forces a strategic pivot in trial
    design—moving beyond the primary endpoint to secondary differentiators captured
    via ECOAs.
  relevance_score: 8
  source: llm_enhanced
  text: Now your ECOA strategy might delve into comorbidities, for example, sleep
    apnea, heart disease, some of those other things. So it adds to the complexity
    of it.
  topic: Strategy/Trial Design
- impact_reason: Highlights the focus on the *infrastructure* layer required to achieve
    'real business impact' from AI.
  relevance_score: 8
  source: llm_enhanced
  text: Join us at Emerge's Vision to Value AI Infrasummit. We're enterprise leaders
    from Google, Microsoft, IBM, and more share how they build, secure, and scale
    AI infrastructure for real business impact.
  topic: AI Infrastructure
- impact_reason: A concise, actionable mantra emphasizing execution over discussion
    regarding AI adoption.
  relevance_score: 8
  source: llm_enhanced
  text: Don't just talk AI, deploy it.
  topic: Actionable Advice
- impact_reason: Provides a concrete example of technology (an 'Accelerator' tool)
    being used to automate and optimize the complex COA selection process based on
    protocol endpoints.
  relevance_score: 8
  source: llm_enhanced
  text: IQVIA has a tool called the ECOA Accelerator, and what that tool does is when
    you put in your endpoints that you're looking for, your concepts... that tool
    will come back and tell you what instrumentation out there can help support that
    concept.
  topic: Tech Solutions/Automation
- impact_reason: 'Draws a parallel between CX/call center optimization and clinical
    trials: reducing HCP burden directly improves the patient experience.'
  relevance_score: 8
  source: llm_enhanced
  text: Patient satisfaction, patient friction is entirely incumbent on what is the
    friction, the burden for the human agent. In this case, the healthcare professional...
  topic: HCP Burden/CX Parallel
- impact_reason: Explicitly names the 'clinician burden' as a critical, often overlooked,
    factor in study design alongside patient burden.
  relevance_score: 8
  source: llm_enhanced
  text: 'You actually nailed both aspects right on the head: the patient burden and
    what we call the clinician burden as well.'
  topic: Burden Metrics
- impact_reason: Highlights the critical role of psychological and social factors
    (stigma) in patient retention, requiring sensitive technology design.
  relevance_score: 8
  source: llm_enhanced
  text: On the obesity side... there's a stigma associated with the obesity as well
    that those patients are dealing with. And so you have to be cognizant of that
    and, you know, keep them engaged, keep them positive about the study...
  topic: Patient Retention/Stigma
- impact_reason: Challenges the necessity of traditional data collection methods (like
    food diaries) if patients perceive them as high-burden and low-value.
  relevance_score: 8
  source: llm_enhanced
  text: They didn't want to do food diaries because they've been doing them all their
    life... it didn't produce anything effective that really supported them and their
    weight loss.
  topic: Data Utility/Patient Perception
- impact_reason: Defines productivity enablement for sites as a top-tier goal for
    technology implementation in clinical operations.
  relevance_score: 8
  source: llm_enhanced
  text: That enabling that productivity for the site is, I think, one of the biggest
    things that we've done to help ease site burden.
  topic: Site Productivity
- impact_reason: A strong warning that technology choice itself introduces friction
    if not carefully managed across the entire patient journey.
  relevance_score: 8
  source: llm_enhanced
  text: No matter what level of technology they're using, this could be a potentially
    very painful point, friction-filled point of the patient experience overall in
    clinical trials.
  topic: Friction/UX Warning
- impact_reason: Reiterates the necessity of holistic journey mapping over optimizing
    individual touchpoints.
  relevance_score: 8
  source: llm_enhanced
  text: It's the journey. It's absolutely correct. That's spot on. It's the entire
    patient journey. You can't just look at one document.
  topic: Journey Mapping
- impact_reason: Directly links using the patient's personal device (BYOD) to reduced
    friction and simpler data collection.
  relevance_score: 8
  source: llm_enhanced
  text: If they can use their primary device, it makes collection of the data a lot
    simpler too.
  topic: BYOD Benefit
- impact_reason: Defines the modern 'COA Library' as a crucial digital asset management
    system for standardized, ready-to-deploy assessments.
  relevance_score: 8
  source: llm_enhanced
  text: I think the COA library is really big, is where you have... everybody can
    have a filing cabinet full of the paper. So when I'm talking about library, I'm
    talking about doing a digital implementation of those COAs.
  topic: Digital Asset Management/COA Library
- impact_reason: 'Directly links regulatory acceptance of BYOD to tangible business
    benefits: cost-effectiveness in data collection.'
  relevance_score: 8
  source: llm_enhanced
  text: And so that really opened the door. It made things a lot more cost-effective
    for collecting data.
  topic: Business/Cost Efficiency
- impact_reason: Focuses on reducing patient burden, a key metric for trial success
    and data quality, by leveraging familiar technology.
  relevance_score: 8
  source: llm_enhanced
  text: So if they can use their primary device, it makes collection of the data a
    lot simpler too.
  topic: User Experience/Data Collection
- impact_reason: Identifies IP management within digital libraries as a crucial, yet
    often overlooked, operational area that is ripe for optimization ('low-hanging
    fruit').
  relevance_score: 8
  source: llm_enhanced
  text: You have to pay people for their intellectual property. So how do you manage
    that library from that standpoint? I think that's one that's kind of like low-hanging
    fruit.
  topic: Business Strategy/Operations
- impact_reason: Establishes the historical context and origin of COAs/PROs, showing
    their long-standing importance in data collection.
  relevance_score: 7
  source: llm_enhanced
  text: Clinical outcome assessments really started back in the late 80s, early 90s
    as a tool to gather clinical information. Typically, in the early days, it was
    gathered from the patient. Those are called PROs, patient-reported outcomes.
  topic: Industry History
- impact_reason: Names specific, industry-standard instruments (EQ-5D, SF-36), valuable
    for professionals needing to know the benchmarks.
  relevance_score: 7
  source: llm_enhanced
  text: The most popular COA, the EQ-5D, is used for assessing people's how they're
    feeling and how they're doing. The SF-36 is another one that's incredibly popular
    for measuring that.
  topic: Technical Detail
- impact_reason: 'Summarizes the core difficulty: the technology might be sound, but
    the operational execution and human element create the complexity.'
  relevance_score: 7
  source: llm_enhanced
  text: It's all the operational things and how do you tell it like that if they can
    make that challenging?
  topic: Operational Insight
- impact_reason: Defines the scope of 'AI leadership' as strategic and decision-making
    roles, not just technical engineering.
  relevance_score: 7
  source: llm_enhanced
  text: You don't need to be an engineer or a technical expert to be on the show.
    If you're involved in AI implementation, decision-making, or strategy within your
    company, this is your opportunity to share your insights.
  topic: Business/Strategy
- impact_reason: Provides insight into the motivation behind an AI tool (NotebookLM)
    focused on knowledge synthesis and connection-making.
  relevance_score: 7
  source: llm_enhanced
  text: As an author, I've always been obsessed with how software could help organize
    ideas and make connections. So we built NotebookLM as an AI-first tool for anyone
    trying to make sense of complex information.
  topic: Technology Philosophy
- impact_reason: Suggests that COA design is a rigorous scientific discipline, not
    just simple form creation.
  relevance_score: 7
  source: llm_enhanced
  text: There's a whole science behind how you identify what questions need to be
    asked and what you can discern from their answers.
  topic: Scientific Rigor
- impact_reason: Illustrates the massive complexity and fragmentation in selecting
    appropriate clinical outcome measures.
  relevance_score: 7
  source: llm_enhanced
  text: There are thousands of them [COAs]. And you might be looking at, you know,
    if you are designing a protocol, you might be looking at 10 or 20 different COAs
    that you want to make a part of your study because there's different elements
    of each one.
  topic: COA Selection Complexity
- impact_reason: Stresses the need for adaptive, context-aware design based on the
    patient's acute condition and treatment side effects.
  relevance_score: 7
  source: llm_enhanced
  text: The oncology patient, you don't want to have a questionnaire of 50 questions
    on there... typically very sick people. The chemotherapy or other therapies takes
    a lot out of them.
  topic: Contextual Design
- impact_reason: A surprisingly specific example of automation that speaks to reducing
    manual effort in compliance and documentation tasks.
  relevance_score: 7
  source: llm_enhanced
  text: You can automate the generation of screenshots.
  topic: Automation/Efficiency
- impact_reason: Self-promotional, but establishes the podcast's authority and target
    audience (executives focused on real-world AI ROI).
  relevance_score: 6
  source: llm_enhanced
  text: The AI and Business Podcast wants to hear from you... We feature hundreds
    of executive thought leaders... With nearly a million annual listeners, AI and
    Business is the go-to destination for enterprise leaders navigating real-world
    AI adoption.
  topic: Business/Media Positioning
- impact_reason: 'Reiterates the core purpose of PROs: quantifying subjective patient
    experience.'
  relevance_score: 6
  source: llm_enhanced
  text: The primary tool for that was to use a COA, or a patient-reported outcome,
    a questionnaire for the patient to answer on how they are feeling.
  topic: Technical Detail
source: Unknown Source
summary: "## Summary of AI and Business Podcast Episode: ECOAs, Oncology, and Obesity\
  \ Trials\n\nThis episode of the AI and Business Podcast, featuring **Anthony Mikolachik,\
  \ VP of Commercial Strategy at IQVIA Technologies**, focuses on the critical role\
  \ and modernization of **Electronic Clinical Outcome Assessments (ECOAs)** in high-stakes\
  \ clinical trials, particularly in **oncology and obesity**. The discussion highlights\
  \ how digitizing these assessments is essential for reducing patient and clinician\
  \ burden, ensuring data quality, and accelerating time-to-insight in these competitive\
  \ therapeutic areas.\n\n### Key Discussion Points and Narrative Arc\n\nThe conversation\
  \ begins by establishing a clear definition of **Clinical Outcome Assessments (COAs)**—sophisticated\
  \ questionnaires (like SurveyMonkey on steroids) used to gather patient-reported\
  \ outcomes (PROs), clinician reports, or caregiver input, gaining prominence after\
  \ FDA mandates around 2011-2012 to measure patient quality of life. The narrative\
  \ then pivots to the unique complexities introduced by oncology and obesity trials,\
  \ which represent the largest R&D spend areas. The core challenge discussed is managing\
  \ the operational hurdles of global deployment, cultural localization, and data\
  \ attribution, which ECOAs are poised to solve through digitization and AI integration.\n\
  \n### Major Topics and Technical Concepts\n\n*   **ECOA Definition and History:**\
  \ Electronic implementation of COAs, evolving from early Palm Pilot applications\
  \ to modern digital tools. Key examples of COAs mentioned include the **EQ-5D**\
  \ and **SF-36**.\n*   **Therapeutic Area Challenges:**\n    *   **Oncology:** Focus\
  \ on measuring quality of life improvements amidst often debilitating treatments.\
  \ Requires high-frequency, culturally adapted data collection across numerous global\
  \ sites.\n    *   **Obesity:** Characterized by an extremely dense pipeline (173\
  \ compounds in development), necessitating differentiation beyond primary endpoints\
  \ (weight loss) into comorbidities. Operational challenges include managing connected\
  \ devices (scales, glucose monitors) and ensuring data attribution (e.g., ensuring\
  \ the correct patient uses the scale).\n*   **Localization and Cultural Nuance:**\
  \ The necessity of adapting assessments beyond mere translation to account for cultural\
  \ context (e.g., technology access like chopsticks vs. iPhones).\n*   **Patient\
  \ and Clinician Burden:** A central theme, emphasizing that trial dropout rates\
  \ are heavily influenced by assessment friction. This includes physical accessibility\
  \ (large buttons for elderly oncology patients) and psychological impact (stigma\
  \ associated with obesity questionnaires, patient aversion to traditional food diaries).\n\
  *   **Technological Solutions:** Discussion of tools like IQVIA’s **ECOA Accelerator**,\
  \ which uses data to recommend the least burdensome combination of instruments based\
  \ on desired endpoints and concepts. The acceptance of **Bring-Your-Own-Device (BYOD)**\
  \ strategies, accelerated by COVID-19, is noted as a major facilitator for reducing\
  \ patient burden.\n\n### Business Implications and Strategic Insights\n\n1.  **Primary\
  \ Endpoint Criticality:** When a COA forms the primary endpoint of a trial, data\
  \ quality, compliance, and collection become non-negotiable for regulatory filing,\
  \ elevating the strategic importance of the ECOA strategy.\n2.  **Competitive Differentiation\
  \ (Obesity):** In crowded fields like obesity, the ECOA strategy must evolve beyond\
  \ primary metrics to capture data supporting secondary endpoints like comorbidities,\
  \ providing necessary differentiators against established or generic competitors.\n\
  3.  **Site Productivity:** Easing **clinician burden** is paramount. This is achieved\
  \ by consolidating technology platforms and implementing proactive compliance monitoring\
  \ systems that automatically flag non-compliant patients, allowing sites to focus\
  \ on patient care rather than manual data auditing.\n\n### Challenges and Recommendations\n\
  \n*   **Challenge:** The sheer volume of available COAs (thousands) makes selection\
  \ complex, often leading to duplicative or overly burdensome assessments.\n*   **Challenge:**\
  \ Operational issues, like ensuring data attribution from shared home devices (scales),\
  \ complicate data integrity.\n*   **Recommendation (Design):** Adopt a **\"patient\
  \ journey\"** perspective rather than focusing on isolated documents. Design assessments\
  \ to be minimally burdensome, considering patient demographics (e.g., eyesight,\
  \ dexterity) and psychological factors (stigma).\n*   **Recommendation (Technology):**\
  \ Consolidate technology stacks to reduce the cognitive load on sites dealing with\
  \ multiple trials, each potentially requiring different tech solutions. Implement\
  \ systems that proactively report compliance status rather than requiring manual\
  \ checks.\n\n### Future Outlook and AI Integration\n\nWhile the discussion touches\
  \ on AI's potential to solve localization problems by understanding cultural nuances\
  \ ahead of time, the immediate focus is on using advanced technology (like the Accelerator\
  \ tool) to **optimize instrument selection** and **automate compliance monitoring**.\
  \ The shift is moving from simply collecting data electronically to leveraging platforms\
  \ that *interpret* the data for the end-user (the site).\n\nThis conversation is\
  \ vital for technology professionals because it illustrates how digital transformation\
  \ in clinical trials is driven not just by engineering capability, but by deep understanding\
  \ of **human factors (patient/clinician experience)** and **regulatory necessity**\
  \ in multi-billion dollar therapeutic areas."
tags:
- artificial-intelligence
- startup
- investment
- google
- microsoft
title: Reducing Errors and Improving Compliance in Global Oncology Programs - with
  Anthony Mikulaschek at IQVIA Technologies
topics:
- keywords:
  - ai
  - machine learning
  - deep learning
  - neural networks
  - llm
  - large language model
  mentions: 51
  prominence: 1.0
  topic: artificial intelligence
- keywords:
  - startup
  - entrepreneur
  - founder
  - venture
  mentions: 1
  prominence: 0.1
  topic: startup
- keywords:
  - investment
  - funding
  - valuation
  - ipo
  - acquisition
  mentions: 1
  prominence: 0.1
  topic: investment
---

<!-- Episode automatically generated from analysis data -->
<!-- Processing completed: 2025-10-04 18:31:24 UTC -->
